As a world leading Chimeric Antigen Receptors (CARs) technique supplier, Creative Biolabs provides CellRapeutics™ fourth generation CARs design service. Our skilled scientists can construct the fourth generation CAR for treating solid tumors and liquid tumors in both preclinical and clinical studies.
Brentjens and Curran. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen Hematology Am Soc Hematol Educ Program. 2012;2012:143-51.
The promising results have been observed by reinfusion of CAR-T cells into different cancer patients, which have attracted more and more attention in clinical oncology area. However, there are still several flaws needed to be overcome before its large-scaled application in clinical trials, such as “on-target, off-tumor” toxicity, cytokines storm. Based on these, our seasoned researchers from Creative Biolabs design the fourth generation CAR to overcome these drawbacks.
In comparison with the previous three generations, our fourth generation CAR is engineered with an inducible expression component such as a cytokine (like IL-12). The CAR-modified T cell (called TRUCK T cell) can release this transgenic protein to regulate T-cell response. The advantage of CAR mediated TRUCK T cells is that cytokine (like IL-12) can increase the activation level of CAR-T cells and also activate innate immune cells to kill the antigen-negative cancer cells. Most importantly, this transgenic cytokine is stored in CAR-T cell and only obtained when it is induced. In addition, we also endue the fourth generation CAR a self-withdrawal mechanism, for instance caspase-9 gene as a suicide gene can be activated to rapidly withdraw CAR-T cells once the anti-tumor effect is achieved.
Creative Biolabs provides different generations of CAR construction services to satisfy your specific needs. Our excellent team is always here and ready to assist you. Please do not hesitate to contact us.
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved